Depomed, Inc has completed enrolment of the phase-3 clinical trial of DM-1796 for the treatment of post-herpetic neuralgia.

"We are glad that we successfully arrived at another milestone that brings Depomed closer to potential milestone payments related to the development of DM-1796 and further royalties and sales milestones upon its approval. We remain excited to have Solvay Pharmaceuticals as a strong and committed partner in the neuroscience field, we share with their expectation that DM-1796 could become a significant product for the treatment of neuropathic pain," said Carl A Pelzel, Depomed's president and chief executive officer.

Dr. Michael Sweeney, Depomed's vice president, Research and Development, added, "I would like to thank all clinical investigators, patients, and Depomed employees whose dedication to DM-1796 enabled us to complete enrolment as planned. We look forward to the top-line results of the trial in the fourth quarter of this year."

In March 2008, Depomed initiated dosing of the first patient in this Phase 3 clinical trial for DM-1796 for PHN. The study is a randomized, double-blind, placebo-controlled study of approximately 450 PHN patients. Patients in the study are randomized into two treatment arms: placebo, or 1800mg of DM-1796 dosed once daily.

Gabapentin available on the market is formulated for immediate release (IR).

Depomed is a specialty pharmaceutical company with two product candidates in phase-3 clinical development, two approved products on the market and other product candidates in its early stage pipeline.

Solvay Pharma of Marietta, Georgia, is the US subsidiary of Solvay Pharmaceuticals.